Skip to main content

Table 2 Changes in mean IOP after 1 week, 1 month, and 3 months of treatment

From: Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China

Time point

IOP parameter

All (n = 285)

Group A (n = 165)

Group B (n = 89)

Group C (n = 31)

Baseline

Mean IOP, mmHg

22.0 ± 4.2

22.4 ± 4.7

21.0 ± 3.5

22.5 ± 3.2

1 week

Mean IOP, mmHg

17.7 ± 3.52

17.1 ± 3.54

18.8 ± 3.47

18.1 ± 2.84

IOP change, mmHg

4.2 (3.7–4.7)

5.0 (4.5–5.5)

2.8 (2.2–3.5)

4.1 (3.0–5.2)

Percentage change, %

17.6 (15.8–19.5)

21.1 (19.1–23.1)

11.2 (8.4–14.0)

17.6 (12.9–22.3)

P value (vs. baseline)

 < 0.001

 < 0.001

 < 0.001

 < 0.001

1 month

Mean IOP, mmHg

18.0 ± 3.9

17.4 ± 3.9

19.0 ± 4.0

17.7 ± 3.1

IOP change, mmHg

4.0 (3.5–4.5)

4.7 (4.2–5.2)

2.5 (1.8–3.2)

4.5 (3.3–5.7)

Percentage change, %

16.7 (14.7–18.7)

19.7 (17.4–22.0)

10.2 (7.1–13.3)

19.6 (14.4–24.9)

P value (vs. baseline)

 < 0.001

 < 0.001

 < 0.001

 < 0.001

3 months

Mean IOP, mmHg

18.2 ± 4.2

17.4 ± 3.9

19.9 ± 4.6

17.6 ± 3.8

IOP change, mmHg

3.7 (3.2–4.3)

4.7 (4.1–5.2)

1.6 (0.9–2.4)

4.6 (3.4–5.9)

Percentage change, %

15.6 (13.5–17.7)

19.8 (17.4–22.2)

6.1 (2.8–9.4)

20.3 (14.7–25.9)

P value (vs. baseline)

 < 0.001

 < 0.001

0.006

 < 0.001

  1. IOP Intraocular pressure
  2. The IOP reduction and percentage calculated in “all patients” are arithmetic average. The IOP reduction and percentage in Group A, B, C are the least square mean (Lsmean), using the analysis of covariance model (ANCOVA), taking the baseline IOP as the covariant and the Group (A, B, C) as the fixed effect